Anticancer Drug Development Guide : Preclinical Screening, Clinical Trials, and Approval (Cancer Drug Discovery and Development) (2 HAR/CDR)

個数:

Anticancer Drug Development Guide : Preclinical Screening, Clinical Trials, and Approval (Cancer Drug Discovery and Development) (2 HAR/CDR)

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 450 p.
  • 言語 ENG
  • 商品コード 9781588292285
  • DDC分類 616.994061

Full Description

This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.

Contents

Part I: In Vitro Methods

High-Volume Screening
Michel Pagé

High-Throughput Screening in Industry
Michael D. Boisclair, David A. Egan, Kety Huberman, and Ralph Infantino

The NCI Human Tumor Cell Line (60-Cell) Screen: Concept, Implementation, and Applications
Michael R. Boyd

Human Tumor Screening
Axel-R. Hanauske, Susan G. Hilsenbeck, and Daniel D. Von Hoff

Part II: In Vivo Methods

Murine L1210 and P388 Leukemias
William R. Waud

In Vivo Methods for Screening and Preclinical Testing: Use of Rodent Solid Tumors for Drug Discovery
Thomas Corbett, Lisa Polin, Patricia LoRusso, Fred Valeriote, Chiab Panchapor, Susan Pugh, Kathryn White, Juiwanna Knight, Lisa Demchik, Julie Jones, Lynne Jones, and Loretta Lisow

Human Tumor Xenograft Models in NCI Drug Development
Michael C. Alley, Melinda G. Hollingshead, Donald J. Dykes, and William R. Waud

NCI Specialized Procedures in Preclinical Drug Evaluations
Melinda G. Hollingshead, Michael C. Alley, Gurmeet Kaur, Christine M. Pacula-Cox, and Sherman F. Stinson

Patient-Like Orthotopic Metastatic Models of Human Cancer
Robert M. Hoffman

Preclinical Models for Combination Therapy
Beverly A. Teicher

Models for Biomarkers and Minimal Residual Tumor
Beverly A. Teicher

Spontaneously Occurring Tumors in Companion Animals As Models for Drug Development
David M. Vail and Douglas H. Thamm

Part III: Nonclinical Testing to Support Human Trials

Nonclinical Testing: From Theory to Practice
Denis Roy and Paul A. Andrews

Nonclinical Testing for Oncology Drug Products
Paul A. Andrews and Denis Roy

Nonclinical Testing for Oncology Biologic Products
Carolyn M. Laurençot, Denis Roy, and Paul A. Andrews

Part IV: Clinical Testing

Working With the National CancerInstitute
Paul Thambi and Edward A. Sausville

Phase I Trial Design and Methodology for Anticancer Drugs
Patrick V. Acevedo, Deborah L. Toppmeyer, and Eric H. Rubin

Phase II Trials: Conventional Design and Novel Strategies in the Era of Targeted Therapies
Keith T. Flaherty and Peter J. O'Dwyer

Drug Development in Europe: The Academic Perspective
Chris Twelves, Mike Bibby, Denis Lacombe, and Sally Burtles

The Phase III Clinical Cancer Trial
Ramzi N. Dagher and Richard Pazdur

Assessing Tumor-Related Symptoms and Health-Related Quality of Life in Cancer Clinical Trials: A Regulatory Perspective
Judy H. Chiao, Grant Williams, and Donna Griebel

The Role of the Oncology Drug Advisory Committee in the FDA Review Process for Oncologic Products
Leslie A. Vaccari

FDA Role in Cancer Drug Development and Requirements for Approval
Susan Flamm Honig

Index